Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Fixed-duration subcutaneous mosunetuzumab demonstrates sustained clinically meaningful outcomes in patients with previously untreated, low-tumor burden follicular lymphoma

View Full Paper
Ask AI
Bookmark
Share

Authors

JVJosé C. VillasboasMWMei WuVCVivek S. Chopra

Discussion

Loading...

Member takes

Overview

Phase II trial shows high progression-free survival in low-tumor burden follicular lymphoma, suggesting mosunetuzumab offers safe outpatient treatment.

Key Points

  • This trial aimed to assess the efficacy and safety of subcutaneous mosunetuzumab in patients with untreated follicular lymphoma.
  • Open-label, multicenter, Phase II study conducted in the US.
  • Patients included those with low-tumor burden follicular lymphoma and ECOG PS 0–2.
  • Mosunetuzumab was administered subcutaneously with step-up dosing; treatment continued based on response.
  • ORR reached 98.0%, with a complete response rate of 89.1%.
  • 12-month progression-free survival was 92.0%.
  • Most common adverse events included injection-site reactions and cytokine release syndrome.

Cite This Study

Villasboas et al. (2025) studied this question.

synapsesocial.com/papers/693624dd4fa91c937236d23chttps://doi.org/10.1182/blood-2025-1807
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Fixed-duration subcutaneous (SC) mosunetuzumab, with maintenance therapy, in patients (pts) with previously untreated high-tumor burden follicular lymphoma (HTB FL): Longer follow-up and exploratory circulating tumor (ct)DNA analysis of the Phase II MorningSun study2025
  2. 2Fixed treatment duration mosunetuzumab continues to demonstrate clinically meaningful outcomes in patients with relapsed/refractory (R/R) follicular lymphoma (FL) after ≥2 prior therapies: 5-year follow-up of a pivotal Phase II study2025
  3. 3Fixed-duration subcutaneous mosunetuzumab continues to demonstrate high rates of durable responses in patients with relapsed/refractory follicular lymphoma after ≥2 prior therapies: 3-year follow-up from a pivotal Phase II study2025 · 1 citations
  4. 4Fixed treatment duration subcutaneous mosunetuzumab monotherapy in elderly/unfit patients with previously untreated diffuse large B-cell lymphoma: Interim results from the Phase II MorningSun study2025 · 6 citations
  5. 5Response-adapted treatment with mosunetuzumab with or without obinutuzumab and polatuzumab vedotin in treatment naïve follicular and marginal zone lymphoma: Final results and phased-seq MRD analysis2025 · 2 citations